Crescent Biopharma develops oncology therapies with multiple modalities for solid tumors. Its lead program, CR-001, is a tetravalent PD-1 × VEGF bispecific antibody intended as an immunotherapy backbone, complemented by antibody-drug conjugates such as PD-L1– and ITGB6-directed ADCs. The company partners internationally to advance combinations and expand its pipeline for patients with difficult-to-treat cancers.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -15.2 | — |
| Q2 2025 | 0 | — | -21.8 | — |
| Q3 2025 | 0 | — | -24.6 | — |
| Q4 2025 | 10.8 | — | -92.4 | — |
| Q1 2026 | 1 | — | -23.3 | — |
| Q2 2026 | 0 | — | -24.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Cerus Corporation (CERS), Malibu Boats, Inc. (MBUU), Infinite Eagle Acquisition Corp. (IEAG), Eupraxia Pharmaceuticals Inc. (EPRX), Idea Acquisition Corp. (IACO), D. Boral Acquisition I Corp. (DBCA)